Chemomab Therapeutics Email Format

Pharmaceutical ManufacturingTel Aviv, Israel11-50 Employees

Chemomab Therapeutics is a clinical-stage biotechnology company in the pharmaceutical industry, based in Qiryat Ono, Tel Aviv, Israel, focused on developing therapeutics for fibro-inflammatory diseases with high unmet need. Its lead program, nebokitug (CM-101), is a first-in-class dual-activity monoclonal antibody that neutralizes the soluble chemokine CCL24, a target implicated in fibrosis and inflammation. Nebokitug has demonstrated disease-modifying potential and has been generally well tolerated across clinical and preclinical studies. The company has reported positive results from four clinical trials and is pursuing a Phase 2 program in primary sclerosing cholangitis with plans for a Phase 3 trial, with the FDA aligned on the study design and regulatory pathway, and with Orphan Drug status for PSC and systemic sclerosis and Fast Track designation for PSC. Chemomab trades on Nasdaq under the ticker CMMB and employs 11-50 people.

Sign up for free to view info

Company overview Employee directory